Diligence memo · auto-generated · as of July 2, 2026
VentiRx Pharmaceuticals Inc.
VentiRx Pharmaceuticals Inc. looks under-valued against its niche peers and is dormant on financing cadence.
Businessfiled
VentiRx Pharmaceuticals Inc. operates in Biotechnology, based in SEATTLE.
No verified homepage on file yet — operating evidence is limited to the public record.
Capital & rounds (filed)filed
VentiRx Pharmaceuticals Inc. has raised $97M in disclosed capital across 4 recorded rounds, aggregated from public filings. Its latest round is modeled as Series C (a $40M–$100M round).
Largest single filing: $51M on 2010-01-08.
Most recent recorded round closed around 2014-09-22.
Valuation (modeled)modeled
Provath models VentiRx Pharmaceuticals Inc. at approximately $614M (range $46M–$1.6B). This is an algorithmic estimate from round sizes and same-niche peers — not a quoted or reported figure.
Read: Under-valued. Modeled value is 0.27× the median modeled value of Series C Biotechnology companies in 2013–2015 (41 peers) — value vs value, same stage and era.
Financing rhythm & timingmixed
Historic cadence: a new round about every 19 months.
Last raise 11.8 yr ago; this sector typically re-raises about every 14 months.
Silent for over 3× the sector's normal cadence.
The last round stepped up 1.2× from the prior — scaling.
Comparablesmixed
Capital scale ranks ahead of 90% of Biotechnology peers (4293 compared).
Modeled value ranks above 85% of those peers.
Closest niche peers: Antigenics LLC/DE, Naurex Inc., Fluidigm Corp, Tengion Inc, Spark Therapeutics, Inc..
Peoplefiled
16 named people on file across officers, directors and signatories.
Risks & flagsmixed
Financing has been silent well beyond sector cadence — possibly defunct, acquired, or paused.
No clearly named CEO/founder/principal in the surfaced records — key-person evidence is thin.